Sangamo’s Gene Regulation Technology Reduces Alzheimer’s-linked Tau Protein

Sangamo’s Gene Regulation Technology Reduces Alzheimer’s-linked Tau Protein
Sangamo Therapeutics‘ gene regulation technology significantly reduced levels of tau – a protein crucial to Alzheimer’s disease (AD) – in laboratory tissue experiments and a mouse model, the company announced. Sangamo’s collaborators from the Massachusetts General Hospital Alzheimer’s Disease Research Center and Harvard Medical School presented the results at the 13th International Conference on Alzheimer’s &

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

    • Jose Marques Lopes says:

      Dear Ina, thank you for your question. ZPF-TF development is most advanced in Huntington’s Disease, of which promising pre-clinical results were presented in 2014. However, the technology is still being developed by Sangamo Therapeutics and Shire aiming to proceed to clinical trials in the future.

Leave a Comment

Your email address will not be published. Required fields are marked *